Navigation Links
Palliative radiotherapy for bone metastases in elderly patients improves quality of life
Date:4/22/2013

Geneva, Switzerland: Giving palliative radiotherapy to elderly patients with painful bone metastases can significantly improve their quality of life, a Dutch researcher told the 2nd Forum of the European Society for Radiotherapy and Oncology (ESTRO) today (Monday).

With the number of elderly patients who suffer from metastatic disease on the increase due to the ageing of the population and the ability to prolong the palliative phase of cancers, this finding has important implications for clinical practice, said Dr Paulien Westhoff from the Department of Radiotherapy at the University Medical Centre Utrecht, The Netherlands.

Together with Dr Yvette van der Linden and colleagues, Dr Westhoff extrapolated the new results from the Dutch Bone Metastases Study, the world's largest randomised trial looking at the effectiveness of different radiotherapy fractionation schedules on the treatment of pain arising from bone metastases. The researchers studied a subset of 227 elderly patients aged 75 and over and compared them with younger patients. Although at entry into the trial these patients had more physical impairment of activity than younger patients, they did not rate their overall quality of life as inferior, and they showed a positive response to a single fraction of radiotherapy.

"The patients filled out extensive questionnaires on pain and quality of life at regular intervals," said Dr Westhoff. "Although we knew already that a single fraction of 8 Gy was effective in treating bone pain across the board, we were unsure as to its precise effect in the elderly, and we were pleased to be able to show that this treatment is effective in all age groups. Even though the elderly group responded slightly less well than the others to the treatment, their response was sufficient to justify the use of palliative radiotherapy in these patients."

Reasons why the elderly group responded less well to the treatment may be related to their poorer performance status when they joined the trial and the higher percentage of male patients, who were more likely to have prostate cancer. Women were more likely to have breast cancer, which often responds better to treatment than lung or prostate cancer.

The three main groups of primary tumours in the patients studied were breast (39%), prostate (23%) and lung cancers (25%). The remaining 13% comprised a variety of primary tumours, such as bladder cancer, rectal cancer, and oesophageal cancer. The group was made up 54% men and 46% women.

"We saw that the type of primary tumour had an effect on the response to treatment," said Dr Westhoff. "For example, patients with lung cancer had less chance of response than those with breast or prostate cancer. We believe that this variety in response is due to the aggressiveness of the disease and the limited ability to treat it with systemic agents."

Bone metastases develop when cancer cells from primary tumours migrate to the bone, causing it to weaken over a period of time. They can cause pain, which can be severe and debilitating, compression of the spinal cord, fractures, spinal instability, anaemia, and significant degeneration of quality of life. Bone is one of the most common places for cancer to spread and, once there, the cancer cells settle in their new environment and continue to grow.

The pain from bone metastases arises through stretching of the periosteum, the membrane lining the external surface of the bone and which contains many nerve endings. The stretching activates pain receptors, and chemical mediators of pain such as prostaglandins also play a role. The precise pain-killing mechanism of radiotherapy in these cases is unknown; it is not solely due to tumour shrinkage, say the researchers, because the onset of response can be very rapid. More likely it is a response mechanism involving chemical mediators such as prostaglandin that causes the pain relief.

"Bone metastases can profoundly disrupt a patient's life, particularly when, as is the case with many elderly, they already have other health problems. Strategies for minimising their effect are vital to improving quality of life," Dr Westhoff said.

"Radiotherapy departments across The Netherlands are trying to set up a prospective database to follow up the effectiveness of a number of palliative treatments. Following these encouraging results in the elderly, we intend to focus on this age group in the future," she concluded.

President of ESTRO, Professor Vincenzo Valentini, a radiation oncologist at the Policlinico Universitario A. Gemelli, Rome, Italy, said: "We know that the pain relief from a single fraction of radiotherapy can reduce patients' morphine consumption. Though morphine is an important drug in the control of tumour pain, it has side-effects such as nausea, constipation, and grogginess, which compromise seriously patients' quality of life. This simple pain control strategy allows the morphine dose to be minimised, and also improves quality of life."


'/>"/>

Contact: Mary Rice
mary.rice@riceconseil.eu
European Society for Radiotherapy and Oncology (ESTRO)
Source:Eurekalert

Related medicine news :

1. Palliative care resource helps ease changes
2. A nurse practitioner-driven palliative care intervention improves cancer patients quality of life
3. Palliative care improves outcomes for seniors
4. Palliative Care Eases Suffering for Seniors at End of Life: Study
5. Interdisciplinary education seeks to improve palliative care
6. Involving other providers in palliative care may help meet growing demand
7. Stem cell sparing radiotherapy for head and neck cancer may avoid salivary gland damage
8. Researchers discover how to overcome poor response to radiotherapy caused by low haemoglobin levels
9. Highly targeted irradiation as good as whole breast radiotherapy in early stage cancer
10. Breathing during radiotherapy - how to hit the treatment target without causing collateral damage
11. Quality of life study shows stereotactic ablative radiotherapy effective treatment; stage I NSCLC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was out ... family verbally and physically. , “When something upset him, he couldn’t control his emotions,” remembers ... would throw rocks at my other children and say he was going to kill them. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. ... accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas of orthodontics, ... and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic ...
(Date:6/24/2016)... ... ... People across the U.S. are sharpening their pencils and honing their writing ... which patients and their families pay tribute to a genetic counselor by nominating him ... Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. , In April, Genome ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® & Innovative Solutions ... initiated cultivation and processing operations at its production facility, and opened its first ... is the manufacturer of a complete system of proactive air and surface purification ...
(Date:6/24/2016)... ... ... Venture Construction Group (VCG) sponsors Luke’s Wings 5th Annual ... Country Club at 1201 Rockville Pike, Rockville, Maryland, 20852. The event raised funds ... been wounded in battle and their families. Venture Construction Group is a 2016 Silver ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)...  VMS Rehab Systems, Inc. ( www.vmsrehabsystemsinc.com ) reported ... required to build a strong and stable market for ... on the OTC Markets-pink current trading platform. ... are seeing an anomaly in market trading activities that ... the Company, but shareholders and market players as well. ...
(Date:6/24/2016)... SAN FRANCISCO, Calif. , June 24, 2016 ... GBT ), a biopharmaceutical company developing novel therapeutics ... significant unmet needs, today announced the closing of ... shares of common stock, at the public offering ... shares in the offering were offered by GBT. ...
(Date:6/24/2016)... ALEXANDRIA, Va. , June 24, 2016 ... a set of recommendations that would allow ... information (HCEI) with entities that make formulary and coverage ... determine the "value" of new medicines. The ... that does not appear on the drug label, a ...
Breaking Medicine Technology: